Biovest International Inc. said cancer vaccine BiovaxID (personalized anti-idiotype vaccine) met its primary endpoint of significantly improving disease-free survival in a multicenter, randomized, controlled Phase III trial of patients with indolent follicular non-Hodgkin's lymphoma (NHL). (BioWorld Today) Read More